donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > AZN AstraZeneca > Company Executives
AZN AstraZeneca
65.120
-0.910-1.38%
Post Mkt Price
65.200
+0.08+0.12%
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Pascal SoriotExecutive Director,Chief Executive Officer13.86M----62male04/29/2022
Dr. Aradhana SarinExecutive Director,Chief Financial Officer3.01M------female04/29/2022
Mr. Adrian C N KempCompany Secretary--------male07/29/2022
Mr. Leif JohanssonNon-Executive Director,Chairman699.00K----70male04/29/2022
Ms. Sherilyn D. McCoyNon-Executive Director127.00K------female04/29/2022
Dr. Andreas RummeltNon-Executive Director40.00K------male04/29/2022
Mr. Marcus WallenbergNon-Executive Director107.00K----65male04/29/2022
Mr. Michel DemareNon-Executive Director148.00K------male04/29/2022
Mr. Philip A J BroadleyNon-Executive Director173.00K----62male07/29/2022
Ms. Diana LayfieldNon-Executive Director92.00K------female04/29/2022
Ms. Deborah DiSanzoNon-Executive Director108.00K------female04/29/2022
Professor Nazneen RahmanNon-Executive Director131.00K------female04/29/2022
Professor Tony MokNon-Executive Director103.00K------male04/29/2022
Dr. Euan AshleyNon-Executive Director103.00K------male04/29/2022
Company Overview More
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
CEO: Soriot M.B.A., Pascal
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...